Lenvatinib Can Overcome Immune Resistance in Head and Neck Cancer and Achieve Durable Remission
Open Access
- 9 March 2023
- journal article
- research article
- Published by Georg Thieme Verlag KG in South Asian Journal of Cancer
Abstract
Squamous cell carcinoma head and neck is the sixth most common cancer worldwide and.[1] Multimodality therapies have been advocated for locoregional relapse or metastatic disease.[2] Combination therapy with lenvatinib has been considered to overcome resistance and improve the efficacy.[3] In a recent study of lenvatinib and pembrolizumab conducted in heavily pretreated recurrent and metastatic head and neck cancer, the median overall survival OS was 6.2 months, and the median progression-free survival (PFS) was 4.6 months.[4] This combination is currently undergoing study in LEAP-010.[5] Herein, we report a case of heavily pretreated metastatic head and neck cancer in a patient who was treated with a combination of lenvatinib with pembrolizumab. Article published online: 09 March 2023 © 2023. MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/) Thieme Medical and Scientific Publishers Pvt. Ltd. A-12, 2nd Floor, Sector 2, Noida-201301 UP, IndiaKeywords
This publication has 4 references indexed in Scilit:
- Combination of pembrolizumab and lenvatinib is a potential treatment option for heavily pretreated recurrent and metastatic head and neck cancerJournal of the Chinese Medical Association, 2021
- Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methodsInternational Journal of Cancer, 2018
- Chemotherapy for recurrent/metastatic head and neck cancersAnti-Cancer Drugs, 2017
- Immunotherapy and Novel Combinations in Oncology: Current Landscape, Challenges, and OpportunitiesClinical and Translational Science, 2016